H.Res. 1072House115th Congress (2017-2019)In Committee

Expressing support for the designation of September 2018 as "Pulmonary Fibrosis Awareness Month".

Introduced September 20, 2018

AI-Generated Summary

Updated April 15, 2026 at 11:44 PM UTC

The resolution asks the House of Representatives to back the designation of September 2018 as Pulmonary Fibrosis Awareness Month. It highlights the seriousness of pulmonary fibrosis, the number of people affected, and the need for more research and support. The measure is aimed at raising public awareness and encouraging continued efforts to improve treatment and care for patients and their families.

Key Provisions

  • Supports officially naming September 2018 as Pulmonary Fibrosis Awareness Month.
  • Affirms the goals of the awareness month, including education and community support.
  • Calls for stronger, faster research to develop better treatments and a cure.
  • Recognizes the contributions of patients who join clinical trials.
  • Commends the work of organizations, volunteers, researchers, and others helping those affected by pulmonary fibrosis.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
HouseIntro Referral Latest Action

Referred to the House Committee on Energy and Commerce.

September 20, 2018

View full timeline
HouseIntro Referral

Introduced in House

September 20, 2018

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

September 20, 2018

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in HouseIssued September 20, 2018

IV

115th CONGRESS

2d Session

H. RES. 1072

IN THE HOUSE OF REPRESENTATIVES

September 20, 2018

Mr. Paulsen (for himself and Mr. Cohen) submitted the following resolution; which was referred to the Committee on Energy and Commerce

RESOLUTION

Expressing support for the designation of September 2018 as Pulmonary Fibrosis Awareness Month.

Whereas pulmonary fibrosis is a debilitating and ultimately fatal lung condition that causes progressive scarring in the lungs and has no definitive cause;

Whereas as many as 200,000 individuals in the United States are known to suffer from pulmonary fibrosis, the majority of whom are aged 50 and older;

Whereas the average life expectancy from the diagnosis of the idiopathic form of pulmonary fibrosis is just 2.8 years, and as many as 80 percent of idiopathic pulmonary fibrosis patients die within 5 years of diagnosis;

Whereas pulmonary fibrosis takes the lives of 40,000 or more individuals in the United States each year—approximately 1 individual every 13 minutes;

Whereas many patients afflicted with pulmonary fibrosis are misdiagnosed for 1 year or longer after the patients are presenting with pulmonary fibrosis symptoms;

Whereas, as of July 2018, there are no confirmed biomarkers for screening and testing for pulmonary fibrosis;

Whereas a cure, treatment, or drug to halt the fibrotic process in pulmonary fibrosis does not yet exist;

Whereas the symptoms of pulmonary fibrosis vary from person to person and include shortness of breath, a dry cough, fatigue, weight loss, and aching muscles and joints;

Whereas volunteers, researchers, caregivers, and medical professionals are working to improve the quality of life for individuals with pulmonary fibrosis and for the families of those individuals; and

Whereas developing more effective treatments for pulmonary fibrosis and providing access to quality care to individuals with pulmonary fibrosis requires increased research, education, and community support services: Now, therefore, be it

That the House of Representatives—

(1)

supports the designation of Pulmonary Fibrosis Awareness Month;

(2)

supports the goals and ideals of Pulmonary Fibrosis Awareness Month;

(3)

continues to support more robust and accelerated research to develop more effective treatments for pulmonary fibrosis and to ultimately find a cure for the disease;

(4)

recognizes the courage and contributions of individuals with pulmonary fibrosis who participate in vital clinical trials to advance the knowledge of the disease; and

(5)

commends the dedication of organizations, volunteers, researchers, and millions of individuals in the United States and abroad working to improve the quality of life for individuals with pulmonary fibrosis and the families of those individuals.